Human genome analysis project to identify risk factors of HBV reactivation following rituximab plus steroids containing chemotherapy (C-SHOT1402)

Human genome analysis project to identify risk factors of HBV reactivation following rituximab plus steroids containing chemotherapy (C-SHOT1402) - Genetic analysis of HBV reactivation after rituximab therapy (C-SHOT1402)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016177

Enrollment

200

Registered

2015-01-15

Start date

2015-01-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Key inclusion criteria meet two either following: 1) A patient who was enrolled in the prospective study to prevent HBV reactivation using HBV DNA monitoring-guided preemptive antiviral therapy. (for an enrolled case for C-SHOT0802; UMIN000001299) 2) A HBsAg-negative patient with malignant lymphoma who was diagnosed as having HBV reactivation following rituximab plus steroid containing chemotherapy as an initial treatment. (if a non-enrolled case for C-SHOT0802)

Exclusion criteria

Exclusion criteria: 1)younger than 19 years old 2)not ability for enough judgement even if 20 years old or older 3) not consciousness even if 20 years old or older 4) careful consideration for the notice of illness is necessary 5) Other conditions considered inappropriate by a physician

Design outcomes

Primary

Measure	Time frame
Host risk factors for HBV reactivation	—

Countries

Japan

Contacts

Public ContactShigeru Kusumoto

Nagoya City University Graduate School of Medical Sciences Department of Hematology and Oncology

skusumot@med.nagoya-cu.ac.jp052-853-8738

Outcome results